TP53 and mantle cell lymphoma: The efficacy of the acadesine-rituximab combination was independent of TP53 mutational status in MCL cells, whereas the synergism effect of acadesine plus bendamustine was higher in cell lines with P53 wild type phenotype, consistently with the known role of P53 in MCL cell response to bendamustine [32].